Table of Contents
October 01, 2025; Volume 92, Issue 10-
From the Editor
-
No surprise, all inflammation is not created equal as it relates to cardiovascular disease
Brian F. Mandell, MD, PhD- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 587-589;
- DOI: https://doi.org/10.3949/ccjm.92b.10025
It is accepted that inflammation is an important component of atherosclerotic cardiovascular disease, but have we found the right inflammatory target for pharmacologic therapy?
-
-
The Clinical Picture
-
Benign migratory glossitis
Jimena Pérez-Rubio, PhD and Ana Laura Ramírez-Terán, PhD- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 591-592;
- DOI: https://doi.org/10.3949/ccjm.92a.24074
A 26-year-old woman presented with well-defined erythematous patches on her tongue that had developed over the previous 6 months.
-
-
1-Minute Consult
-
Do patients with severe community-acquired bacterial pneumonia benefit from systemic corticosteroids?
Alejandro Chapa-Rodriguez, MD, Tark Abou-Elmagd, MD, MSc, MBBCh, Cody O’Rear, DO and Shraddha Narechania, MD- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 600-604;
- DOI: https://doi.org/10.3949/ccjm.92a.25023
Recent evidence has swung the pendulum back in favor of using corticosteroids in patients with severe community-acquired pneumonia.
-
-
Editorial
-
Nearly a century of using glucocorticoids in patients with active infection
Adam J. Brown, MD- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 605-608;
- DOI: https://doi.org/10.3949/ccjm.92a.25074
Why would we consider dampening the immune response with glucocorticoids when a patient has an active infection?
-
-
Review
-
Low-dose colchicine for management of coronary artery disease
Abhayjit Singh, MD, Vikas Sunder, MD and Leslie Cho, MD- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 609-618;
- DOI: https://doi.org/10.3949/ccjm.92a.25005
Current guidelines endorse adding low-dose colchicine to standard medical therapy for coronary artery disease prevention, but data show clinicians remain hesitant to use it for this indication.
-
Hold ACE inhibitors and ARBs before noncardiac surgery? Emerging evidence suggests a patient-specific approach
Maureen Keshock, MD, MHSA, Elise Zhang, MS-3, Christopher Whinney, MD and Kenneth C. Cummings III, MD, MS- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 619-626;
- DOI: https://doi.org/10.3949/ccjm.92a.25035
Judicious withholding of ACE inhibitors and ARBs in vulnerable populations—and promptly resuming them—may strike the safest balance between renal protection and hemodynamic stability.
-
MDA5 dermatomyositis: Unveiling a potentially life-threatening disease
Soumya Chatterjee, MD, MS- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 627-637;
- DOI: https://doi.org/10.3949/ccjm.92a.25018
Timely diagnosis and initiation of aggressive immunosuppressive therapy are key to improving the 40% overall mortality rate in patients with MDA5 dermatomyositis.
-
-
Corrections
-
Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period?
- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 593;
-
Glucagon-like peptide-1 receptor agonists and pancreatitis: A reconcilable divorce
- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 593;
-
Collaborative musculoskeletal care: The role for chiropractors
- Cleveland Clinic Journal of Medicine October 2025, 92 (10) 593;
-
